Triple Therapy of Low-Dose Isotretinoin + Spironolactone + Diammonium Glycyrrhizinate Clears 90.6% of Hormonal Acne in 112 Women

A 112-woman randomized trial in moderate-to-severe acne with hyperandrogenism compared low-dose isotretinoin alone, + spironolactone, + diammonium glycyrrhizinate (DG), and the triple combination. The triple-therapy arm cleared 90.6% of lesions on average versus 58.4% for monotherapy, a 1.55x improvement (Dermatology Times Journal Digest, April 2026). The data position multi-mechanism low-dose combination as a new standard candidate for hormonal acne, a stubborn target where single-agent care has long fallen short.

The trial randomized 112 women with moderate-to-severe acne and hyperandrogenism into four arms. Triple combination produced 90.6% lesion clearance, isotretinoin + spironolactone 78.3%, isotretinoin + DG 71.2%, and isotretinoin alone 58.4%. Adverse events: 13.0% in the monotherapy arm (mostly cheilitis and transient liver enzyme elevation), 8.9% in the triple arm (mild hypotension with spironolactone, with DG buffering some side effects).

Hormonal Acne — Common and Hard to Treat

Why it’s different:

Standard acne: pubertal — sebum, keratin, bacteria, inflammation
Hormonal acne: androgen excess drives sebaceous gland activity and follicular occlusion
Distributes along jawline, chin, and neck
Worsens and improves with menstrual cycle
Responds poorly to conventional antibiotics and BPO

The 25-35 demographic:

30-50% prevalence among women aged 25-35
60-70% of those are hormonally driven
30-40% comorbid with PCOS
Hyperandrogenism is frequently undiagnosed

Limitations of existing therapies:

Antibiotics: 4-6 month efficacy, then resistance and relapse
Topical retinoids: irritation, pregnancy contraindicated
Combined oral contraceptives: depression, thrombosis, weight concerns
Isotretinoin: powerful but high side-effect burden, absolute pregnancy contraindication

Triple Therapy — Three Mechanisms in Parallel

1. Low-dose isotretinoin:

Vitamin A derivative, directly suppresses sebaceous glands
0.25-0.4 mg/kg/day balances safety and efficacy
Normalizes follicular keratinization, anti-inflammatory
Common side effects: cheilitis, transient transaminase elevation
Absolute teratogen — pregnancy forbidden

2. Spironolactone:

Aldosterone antagonist, blocks androgen receptors
50-200 mg/day standard for acne
Reduces androgen-driven sebum production
Side effects: hypotension, hyperkalemia (diuretic action)
Contraception advised in women of reproductive age (low risk to fetus but recommended)

3. Diammonium glycyrrhizinate (DG):

Licorice-derived; hepatoprotectant and anti-inflammatory
Active form of glycyrrhetinic acid
Inhibits 11β-HSD (cortisol regulator), anti-inflammatory effect
Buffers isotretinoin’s liver impact
Side effects: mild edema in some patients

Why the combination synergizes:

Isotretinoin: directly inhibits sebaceous glands
Spironolactone: blocks hormonal (androgen) signaling
DG: anti-inflammatory plus hepatoprotection
Three axes attacked simultaneously
Each axis alone is insufficient for hormonal acne

Clinical Results — What 90.6% Clearance Means

1. Triple combination 90.6% clearance:

“Clearance” defined as ≥90% lesion reduction
Composite of clinical photography, lesion counts, patient assessment
Endpoint around weeks 12-16
90.6% is exceptionally high for hormonal acne

2. 1.55x advantage over monotherapy:

Isotretinoin alone 58.4% → triple 90.6%
Non-responders and partial responders cut roughly in half
Clinically obvious advantage

3. Adverse events 8.9% — lower than monotherapy:

Counterintuitively, triple therapy had fewer side effects
DG’s hepatoprotection and anti-inflammatory effect buffered isotretinoin AE
Spironolactone’s anti-androgen effect reduced sebaceous load
Multi-mechanism approach permitted lower individual doses

Realistic Application

Who fits:

Women aged 25-40
Predominantly jawline and chin acne
Cyclical with menstrual periods
Failed antibiotics and topical retinoids
Comorbid PCOS or hyperandrogenism
No pregnancy plans, willing to use contraception

Workflow:

Gynecologic hormone panel (testosterone, DHEA, SHBG)
Dermatologic confirmation of hyperandrogenism
Triple prescription with liver function, potassium, and pregnancy monitoring
Reassessment at 12-16 weeks

Limitations and Safety

Study limitations:

112 patients, single-center — needs larger multinational replication
East Asian distribution unspecified
No long-term (1-2 year) relapse data
Triple-therapy cost and access not assessed

Pregnancy — the critical constraint:

Isotretinoin: absolute contraindication (severe teratogenicity)
Spironolactone: pregnancy risk (male fetus feminization)
DG: relatively safe but limited data
Reproductive-age women: dual contraception, monthly pregnancy testing required

Side effect management:

Cheilitis: frequent petrolatum and lip balm
Liver function: ALT/AST every 1-3 months
Potassium: check at week 4 of spironolactone
Hypotension: report dizziness immediately

The Bigger Picture — Paradigm Shift in Hormonal Acne Care

Old pattern:

Single agent, high dose
More side effects, more dropouts
Frequent relapse

New paradigm:

Multi-target, low-dose combination
Synergistic efficacy
Lower per-drug side effect burden
Higher response, lower relapse

Clinical outlook for Asia:

Combined gynecology and dermatology care will expand
Could become standard care for PCOS-associated acne
DG and similar adjuncts may become routine prescribing companions
Pre-treatment pregnancy planning will be reinforced

Adjacent: ibutalidine + metformin for PCOS:

Treats PCOS itself (weight, glucose)
Acne is a side benefit
Combinable with the triple therapy for parallel PCOS-plus-acne management

Bottom Line

Hormonal acne does not yield to a single drug. The trial demonstrates this in stark contrast: 90.6% versus 58.4%. A multi-target approach targeting sebum, hormones, and inflammation simultaneously outperformed single-agent strong prescribing — and was safer. The caveats are non-negotiable: pregnancy planning, liver function monitoring, and contraception. For women aged 25-40 with hormonal acne, this trial makes a combined gynecology-dermatology consultation a serious consideration.